ALLIANCE-A091401-EXPANSION
Regimen
- Experimental
- Nivolumab 240 mg Q2W; or nivolumab 3 mg/kg + ipilimumab 1 mg/kg Q3W x 4 then nivolumab maintenance
- Control
- randomised non-comparative
Population
Metastatic sarcoma expansion cohorts enriched for histologies signalling in original A091401: undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, and dedifferentiated/other chondrosarcoma
Key finding
Expansion confirmed combination IO outperforms monotherapy in selected soft-tissue histologies but did not rescue bone-sarcoma activity. Dedifferentiated chondrosarcoma responses support 'dedifferentiated' as a candidate IO-sensitive bucket.
Source: PMID 39343511